医疗事务的评价(美国)- 动脉硬化性心血管疾病
市场调查报告书
商品编码
1798376

医疗事务的评价(美国)- 动脉硬化性心血管疾病

Medical Affairs Reputations (US) - Atherosclerotic Cardiovascular Disease

出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

这项针对美国心臟科专家的最新调查显示,一些主要品牌的动脉粥状硬化性心血管疾病医疗事务团队在几个关键领域的表现仍有提升空间。我们探讨了医师认为哪些方面做得好,哪些方面希望改进,以及不满意的原因。本报告阐明了医疗事务如何满足动脉粥状硬化性心血管疾病医师的高期望。我们比较了各公司在主要动脉粥状硬化性心血管疾病领域医疗事务团队的现况。

关键问题

  • 1.医师与医疗事务团队的互动频率为何?这个频率是在增加还是在减少?
  • 2.医师目前如何使用医疗事务团队提供的服务?
  • 3.医疗事务支援的哪些面向对医师来说最重要?他们对所提供的支援有多满意?
  • 4.医师希望与医疗事务团队进行哪种类型的互动?这种互动的频率是多少?
  • 5.医疗事务团队在多大程度上满足了医师的需求?
  • 6.医疗事务团队的表现是否低于或超过了特定品牌的目标?
  • 7.未来如何改善医疗事务服务,以便更好地满足医师的需求?
  • 8.竞争对手的医疗事务团队在哪些方面最薄弱,哪些方面最强?

领导品牌

  • Lek比奥
  • puraruento
  • repasa
  • toringoruza·apabetaron
  • AZD0780
  • enrishitaido
  • re正硅烷
  • obisetorapibu
  • orupashiran
  • perakasen
  • jirutibukimabu

研究方法

FirstView 报告是基于透过 LiMATM 甄选医师进行的定量调查而得出。 LiMATM 是全球最大的医生名录,涵盖超过 300 万名医生。每位医生均根据严格的筛选标准精心挑选,以确保收集到的见解具有相关性和可靠性,能够反映顶尖医疗专业人士的真实感受和经验。调查结果以易于理解的图表形式呈现,方便您快速掌握和分析数据。凭藉 LiMATM 广泛的覆盖范围和准确性,FirstView 报告可提供无与伦比的数据驱动洞察,指导策略规划,并帮助您在快速发展的医疗保健领域保持领先地位。

报告特色

FirstView Reports 是值得信赖的行业领导者,专注于製药业,为生物製药专业人士和决策者提供深入可行的洞察。我们深厚的行业知识使我们能够提供相关且有价值的洞察,帮助客户掌握新兴趋势,有​​效应对复杂课题。我们的报告以广泛的研究以及来自顶尖专家和关键意见领袖 (KOL) 的独立、公正的见解为后盾,能够提供您所需的准确性和可靠性。独家访谈和数据,以及持续的市场监测,确保您能够全面了解市场动态。我们的报告涵盖 40 多个活跃的疾病领域,包括 KOL 洞察和定量医生调查在内的医生情报,以及行业专家对医疗事务、数位健康、销售和行销、市场准入等领域问题的看法,帮助您做出更明智的数据驱动决策,并在快速变化的行业中保持竞争力。

简介目录

According to this latest survey of US cardiologists, the performance of Atherosclerotic Cardiovascular Disease medical affairs teams for some high profile brands still has a way to go in some key areas. Find out what physicians think is done well; what they want to see more of; and why some are dissatisfied. This report reveals how medical affairs can better meet the high expectations of physicians treating Atherosclerotic Cardiovascular Disease. It compares the current performance of medical affairs teams for several leading treatments for Atherosclerotic Cardiovascular Disease from various companies.

Key Questions Answered:

  • 1. How frequently do physicians interact with Medical Affairs teams, and is the frequency of this interaction increasing or decreasing?
  • 2. In what ways do physicians currently use the services provided by Medical Affairs teams?
  • 3. What aspects of Medical Affairs support are most important to physicians and how satisfied are they with the support provided?
  • 4. What are the preferred mediums for interactions between physicians and Medical Affairs teams and what is the preferred frequency of these interactions?
  • 5. How successful are Medical Affairs teams at meeting physician needs?
  • 6. Are Medical Affairs teams falling short or exceeding goals with any particular brands?
  • 7. How can Medical Affairs services be improved to better meet the needs of physicians in the future?
  • 8. In what areas are your competitors' Medical Affairs teams weakest and strongest?

Key Brands:

  • Leqvio
  • Praluent
  • Repatha
  • Tryngolza apabetalone
  • AZD0780
  • enlicitide
  • lepodisiran
  • obicetrapib
  • olpasiran
  • pelacarsen
  • ziltivekimab

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.